[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"icas---intracranial-atherosclerosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:icas---intracranial-atherosclerosis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,74,97,130,156],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100616754","mpr-for-stroke-risk-assessment-of-icas-100616754",false,"NCT07309718","MPR for Stroke Risk Assessment of ICAS","MRI-Derived Pressure Ratio: a Novel Noninvasive Hemodynamic Biomarker for Stroke Risk Stratification in Intracranial Atherosclerotic Stenosis","Inclusion Criteria:\n\n1. Adults aged 18 to 80 years.\n2. Intracranial atherosclerotic stenosis ICAS involving a culprit artery in the anterior circulation.\n3. Intracranial arterial stenosis of 50% to 99% as measured by the WASID method using TCD, CTA, MRA, or DSA.\n4. Written informed consent obtained from the participant or a legal representative.\n\nExclusion Criteria:\n\n1. Non-atherosclerotic intracranial lesions, including moyamoya disease, vasculitis, vascular dissection, autoimmune diseases, or congenital\u002Fgenetic abnormalities.\n2. More than 50% stenosis of the extracranial carotid artery on the ipsilateral side.\n3. Large cerebral infarction involving more than one-half of the territory on DWI imaging, or a baseline modified Rankin Scale score ≥3.\n4. Contraindications to antiplatelet therapy or statins.\n5. Inability to undergo MRI due to metal implants or claustrophobia.","ALL","18 Years","80 Years",{"count":20,"type":21},400,"ESTIMATED","12 Months","OBSERVATIONAL","Intracranial atherosclerotic stenosis (ICAS) carries substantial stroke risk despite optimal medical treatment. Current risk stratification relies primarily on stenosis severity, but novel hemodynamic markers may improve prediction. In this multiple prospective registry study we aim to investigate whether regional hemodynamics, measured by a novel Magnetic resonance imaging-derived Pressure Ratio (MPR) technique, are associated with stroke risk in ICAS.",[26,27,28],"ICAS - Intracranial Atherosclerosis","Stroke Ischemic","Hemodynamic",[26,27,28,30],"Pressure ratio","RECRUITING","2025-12-15",{"date":34,"type":35},"2025-12-30","ACTUAL",{"date":37,"type":35},"2025-12-01",{"date":39,"type":21},"2028-03-31",{"name":41,"class":42},"Xuanwu Hospital, Beijing","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100570085","a-randomized-clinical-trial-on-urgent-angioplasty-for-intracranial-atherosclerotic-stenosis-related-large-vessel-occlusion-after-mechanical-thrombectomy-100570085","NCT06702657","A Randomized Clinical Trial on Urgent Angioplasty for IntraCranial Atherosclerotic Stenosis-related Large-Vessel Occlusion After Mechanical Thrombectomy","A Randomized Clinical Trial on Urgent Angioplasty for IntraCranial Atherosclerotic Stenosis-related Large-Vessel Occlusion After Mechanical Thrombectomy (ICAS LVO-MT)","ICAS LVO-MT","Inclusion Criteria:\n\nClinical inclusion criteria:\n\n1. Age ≥ 18 years\n2. National Institutes of Health Stroke Scale (NIHSS) score ≥6 before randomization\n3. To receive mechanical thrombectomy \\\u003C24 hours after AIS onset according to local guidelines\n4. Signed informed consent form obtained from the subject (or approved surrogate)\n\nImaging inclusion criteria:\n\n1. For subjects with anterior circulation stroke, ASPECTS ≥6 based on CT or DWI\n2. For subjects with posterior circulation stroke, posterior circulation ASPECTS (pc-ASPECTS)≥6 and pons-midbrains index (PMI) \\\u003C 3 based on CT or DWI\n\nAngiography inclusion criteria:\n\n1. The responsible occluded vessel is immediately recanalized (eTICI≥2b) after mechanical thrombectomy, ICAS is highly suspected and the focal residual stenosis of the main trunk is≥70%, and the responsible occluded vessels include the intracranial segment of the internal carotid artery, the M1 segment of the middle cerebral artery, the V4 segment of the vertebral artery, and the basilar artery\n2. According to the judgment of the neurointerventional physician, the responsible artery is suitable for stenting angioplasty\n\nExclusion Criteria:\n\n1. Pre-stroke mRS \\>2\n2. Intracranial hemorrhage confirmed by CT before mechanical thrombectomy and enrolment\n3. Suspected Intracranial hemorrhage after successful recanalization confirmed by 3D-CT\n4. Tandem lesions: stenosis (or occlusion) of the extracranial segment of the internal carotid artery or vertebral artery combined with occlusion of large intracranial vessels, stenosis of intracranial arteries combined with occlusion of vessels distal to the stenosis\n5. More than two severe stenosis of the responsible occluded vessel (internal carotid artery, middle cerebral artery, vertebral artery, and basilar artery)\n6. Potential cardiac sources of emboli such as atrial fibrillation, left ventricular thrombus, heart valve replacement, atrial septal defect, ventricular septal defect, atrial myxoma, etc.\n7. Current use of oral anticoagulants\n8. Major surgery or serious trauma in the previous 2 weeks\n9. Contraindication for mechanical thrombectomy or stenting angioplasty\n10. Contraindication for antiplatelet treatment or allergy to contrast agent\n11. History of gastrointestinal or urinary bleeding in the previous 3 weeks\n12. Life expectancy less than 1 years\n13. Current pregnant or breastfeeding status\n14. Currently participating in another clinical trial that may affect the outcome assessment of this trial\n15. Any other condition that, in the investigator's judgement, deems the individual unsuitable for enrolment.",{"count":53,"type":21},612,"INTERVENTIONAL",[56],"NA","A prospective, multicenter, randomized controlled, open-label, blinded outcome evaluation (PROBE) trial",[59,26,60],"AIS","Stroke",[62,59,63],"ICAS","STROKE","NOT_YET_RECRUITING","2025-03-14",{"date":67,"type":35},"2025-03-18",{"date":69,"type":21},"2025-03-15",{"date":71,"type":21},"2027-08-15",{"name":73,"class":42},"Changhai Hospital",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":43},"100583829","a-prospective-multicenter-registry-study-on-basis-technique-for-endovascular-therapy-of-acute-large-vessel-occlusion-strokes-due-to-intracranial-atherosclerotic-disease-100583829","NCT06881420","A Prospective Multicenter Registry Study on BASIS Technique for Endovascular Therapy of Acute Large Vessel Occlusion Strokes Due to Intracranial Atherosclerotic Disease","A Prospective Multicenter Registry Study on BASIS Technique for Endovascular Therapy of Acute Large Vessel Occlusion Strokes Due to Intracranial Atherosclerotic Disease (BASIS-DUO)","Inclusion Criteria:\n\n* Age ≥18 years old;\n* Ischemic stroke;\n* Within 72 hours from the onset of symptoms to the time of visit, including post-awakening stroke or blindness For stroke patients, the time when symptoms start is defined as \"the last normal time\";\n* Neuroimaging examination indicated occlusion of anterior or posterior intracranial large vessels, TOAST type was large atherosclerosis type.\n* BASIS technique was used for intravascular therapy.\n\nExclusion Criteria:\n\n* Neuroimaging findings on admission, acute occlusion of multiple vessels and tandem lesions;\n* History of atrial fibrillation or heart valve surgery;\n* There are clinical contraindications to the use of antiplatelet drugs (hemophilia or thrombocytopenia).Rare disease, known history of coagulation disorders, platelet abnormalities; There is active internal bleeding, intracranial Bleeding history, arteriovenous malformation, aneurysm, etc.);\n* Other types of stroke, including hemorrhagic stroke.",{"count":82,"type":21},250,"This study will explore the safety and efficacy of BASIS technology in ICAS-LVO lesions through a multicenter, prospective, registry, observational single-arm study.By registering intraoperative recanalization using this technique time, recanalization grade, operative thrombectomy times, intraoperative complications perforating branch occlusion, vascular dissection, vascular rupture, Ectopic thrombus, probability of symptomatic intracranial hemorrhage, mRS Score and mortality rate were followed up for 3 months The unique advantages of the application of the assessment BASIS in this type of lesion provide new insights into complex lesions such as ICAS-LVO The thought and operation method can shorten the operation time, improve the good prognosis, reduce the economic burden and reduce the operation Complications make a positive contribution to ensure that patients receive safe, effective and precise treatment.",[85,26],"Acute Ischemic Stroke",[85,26,87,88],"Endovascular thrombectomy","BASIS","2025-03-11",{"date":67,"type":35},{"date":92,"type":35},"2024-01-01",{"date":94,"type":21},"2025-12-31",{"name":96,"class":42},"Fujian Medical University Union Hospital",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":54,"phases":108,"briefSummary":109,"conditions":110,"keywords":115,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":129},"100435326","drug-eluting-stenting-and-aggressive-medical-treatment-for-preventing-recurrent-stroke-in-intracranial-atherosclerotic-disease-trial-100435326","NCT04948749","Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial","Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial: a Prospective, Randomized, Open-labelled, Blinded End-point Trial (DREAM-PRIDE)","DREAM-PRIDE","Inclusion Criteria:\n\n1. Age from 18 to 85 years\n2. Patients with ischemic stroke within 30 days of enrolment attributed to 70% to 99% stenosis of a major intracranial artery (internal carotid artery \\[C4-C7\\], middle cerebral artery \\[M1\\], vertebral artery \\[V4\\], or basilar artery) on CTA (According to WASID method)\n3. The diameter of the target vessel between 2.0mm - 4.5mm\n4. The stenosis lesion length ≤ 14 mm\n5. Baseline modified Rankin Scale (mRS) score ≤ 3\n6. Patient understands the purpose and requirements of the study, and has provided informed consent\n\nExclusion Criteria:\n\n1. Ischemic stroke occurred within 7 days before enrolment\n2. Tandem extracranial or intracranial stenosis (70%-99%) or occlusion that is proximal or distal to the target intracranial lesion (NOTE: an exception is allowed if stenosis or occlusion involves a single vertebral artery proximal to a symptomatic basilar artery stenosis and the contralateral vertebral artery is supplying the basilar artery)\n3. Bilateral intracranial vertebral artery stenosis of 70%-99% and uncertainty about which artery is symptomatic (NOTE: an exception is that if bilateral vertebral arteries with 70%-99% stenosis but unequal in size, the dominant side is considered as symptomatic)\n4. Unilateral vertebral artery stenosis of 70%-99% with normal contralateral vertebral artery\n5. Stroke caused by perforating artery occlusion\n6. CT angiographic evidence of severe calcification at target lesion\n7. Any history of brain parenchymal or subarachnoid, subdural or extradural haemorrhage in the past 6 weeks\n8. Intracranial artery stenosis caused by non-atherosclerotic lesions, including: arterial dissection, Moyamoya disease, vasculitis disease, herpes zoster, varicella-zoster or other viral vascular diseases, neurosyphilis, any other intracranial infections, any intracranial stenosis related to cerebrospinal fluid cells, radiation-induced vascular disease, fibromuscular dysplasia, sickle cell disease, neurofibromatosis, central nervous system benign vascular disease, postpartum vascular disease, suspected vasospasm, suspicious embolism recanalization, etc\n9. History of stenting of an intracranial artery\n10. Presence of any unequivocal cardiac source of embolism\n11. Combined with intracranial tumor, aneurysm or intracranial arteriovenous malformation\n12. Cannot tolerate dual antiplatelet therapy\n13. Contraindications to heparin, rapamycin, contrast and local or general anesthesia\n14. Hemoglobin\\\u003C100g\u002FL, platelet count \\\u003C100×109\u002FL\n15. Severe hepatic and renal dysfunction\n16. INR\\>1.5 or there are uncorrectable factors leading to bleeding\n17. Major surgery within the past 30 days or planned within 90 days\n18. Renal artery, iliac artery, and coronary artery requiring simultaneous intervention\n19. Life expectancy \\\u003C1 year\n20. Pregnant or lactating women\n21. Cannot complete the follow-up due to cognitive, emotional or mental illness\n22. Other situations that are not suitable for enrolment according to the judgement of the investigator\n23. Enrolment in another study that would conflict with the current study","85 Years",{"count":107,"type":21},792,[56],"The aim of DREAM-PRIDE is to evaluate whether implantation of drug-eluting stent (DES) combined with aggressive medical treatment is more efficacious in prevention of 1-year stroke recurrence than standard medical treatment alone for symptomatic intracranial atherosclerotic disease.",[111,26,112,60,113,114],"ICAD - Intracranial Atherosclerotic Disease","Drug-eluting Stent","Drug Eluting Stents (DES)","Medical Treatment",[60,116,117,118,119,113],"Drug-eluting stent","Medical treatment","ICAD-Intracranial Atherosclerotic Disease","ICAS-Intracranial Atherosclerosis","2024-12-25",{"date":122,"type":35},"2024-12-27",{"date":124,"type":35},"2021-07-02",{"date":126,"type":21},"2026-12",{"name":128,"class":42},"Beijing Tiantan Hospital",18,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":136,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":43},"100491321","feedback-loop-between-intracranial-atherosclerosis-and-cerebral-small-vessel-disease-100491321","NCT05677607","Feedback Loop Between Intracranial Atherosclerosis and Cerebral Small Vessel Disease","Inclusion Criteria:\n\n* Age ≥ 18 years\n* At least one intracranial artery ≥ 50% atherosclerotic stenosis\n* Modified Rankin Scale \\\u003C 2\n* Mini-mental State Examination \\> 24\n\nExclusion Criteria:\n\n* Concurrent ipsilateral extracranial artery ≥ 50% stenosis\n* Pregnant women\n* Contraindications to magnetic resonance examination (patients with pacemakers, nerve stimulators, artificial metal heart valves and other metal foreign bodies)","30 Years",{"count":138,"type":21},300,"The present study aims at verifying the mutual effects between intracranial large artery atherosclerosis and cerebral small vessel disease on disease progression and prognosis by magnetic resonance imaging, and providing biomarkers for the early prevention and treatment of cerebrovascular disease.",[26,141],"Cerebral Small Vessel Diseases",[143,144,145,146],"Intracranial atherosclerosis","Cerebral small vessel disease","Feedback mechanism","Multimodal MRI","2024-06-30",{"date":149,"type":35},"2024-07-03",{"date":151,"type":35},"2023-01-01",{"date":153,"type":21},"2027-12-31",{"name":155,"class":42},"Chinese PLA General Hospital",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":136,"maxAge":18,"enrollmentInfo":162,"targetDuration":4,"studyType":54,"phases":164,"briefSummary":165,"conditions":166,"keywords":167,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":4},"100514096","intracranial-angiography-derived-fraction-flow-guided-percutaneous-transluminal-angioplasty-and-stenting-versus-medical-therapy-icas-mt-100514096","NCT05974033","IntraCranial Angiography-derived Fraction Flow-guided Percutaneous Transluminal Angioplasty and Stenting Versus Medical Therapy (ICAS-MT)","Inclusion Criteria:\n\n1. Age ≥30 and ≤80 years old.\n2. Symptomatic intracranial atherosclerotic stenosis: Transient ischemic attack (TIA) or stroke related to 70%-99% stenosis in the major intracranial arteries (intracranial segment of the internal carotid artery, M1 segment of the middle cerebral artery, V4 segment of the vertebral artery, and basilar artery) within the past 3 months.\n3. Only one target vessel with 70-99% stenosis confirmed by angiography for enrollment in the trial (WASID criteria).\n4. Patients with ischemic stroke should be performed with stenting beyond a duration of 2 weeks from the latest ischemic symptom onset, patients with TIA have no time restriction.\n5. Pre-enrollment modified Rankin Scale (mRS) score ≤2.\n6. Target vessel reference diameter must be measured to be 2 mm to 4.5 mm, target area of stenosis is less than or equal to 14mm in length.\n7. Patients required to meet at least with one atherosclerotic risk factors, including hypertension, diabetes, hyperlipidemia, hyperhomocysteinemia, coronary heart disease, obesity, smoking history, and atherosclerosis in other arterial vessels.\n8. Negative pregnancy test in a female who has had any menses in the last 18 months.\n9. Patient is willing and able to return for all follow-up visits required by the protocol.\n10. Patient understands the purpose and requirements of the study, can make him\u002Fherself understood, and has provided informed consent.\n\nExclusion Criteria:\n\n1. Intracranial arterial stenosis not caused by atherosclerotic lesions, such as arterial dissection, moya-moya disease, vasculitic disease, viral vascular lesions (e.g., herpes zoster, varicella), neurosyphilis, other intracranial infections, radiation-induced vasculopathy, fibromuscular dysplasia, sickle cell disease, neurofibromatosis, benign central nervous system vascular diseases, postpartum angiopathy, suspected vasospastic process, suspected recanalized embolus, etc.\n2. Any conditions that precludes proper angiographic assessment.\n3. Preoperative MRI indicating only lacunar infarction in the target lesion territory.\n4. History of subarachnoid hemorrhage, subdural or epidural hematoma within 30 days prior to enrollment, or untreated chronic subdural hematoma thickness≥5mm, or history of primary intracerebral hemorrhage.\n5. At risk of hemorrhagic transformation during the procedure (CT or MRI showing infarct area diameter \\>5 cm); hemorrhagic transformation of an ischemic stroke within the past 15 days (detected by CT).\n6. Tandem extracranial or intracranial stenosis (70%-99%) or occlusion that is proximal or distal to the target intracranial lesion\n7. Bilateral intracranial vertebral artery stenosis of 70%-99% and uncertainty about which lesion is symptomatic (for example, if patient has pon, midbrain, temporal and occipital symptoms).\n8. Stenting, angioplasty, or endarterectomy of an extracranial (carotid or vertebral artery) or intracranial artery within 30 days prior to expected enrollment date.\n9. Previous treatment of target lesion with a stent, angioplasty, or other mechanical device, or plan to perform staged angioplasty followed by stenting of target lesion\n10. Severe vascular tortuosity, severe calcification, or other factors that would preclude the safe introduction of a guiding catheter, guiding sheath or stent placement.\n11. Presence of intraluminal thrombus proximal to or at the target lesion.\n12. Any aneurysm proximal to or distal to intracranial stenotic artery.\n13. Intracranial tumors or any intracranial vascular malformations.\n14. Potential cardiac sources of emboli such as atrial fibrillation, left ventricular thrombus, heart valve replacement, atrial septal defect, ventricular septal defect, atrial myxoma, etc.\n15. Myocardial infarction within previous 30 days.\n16. Suspected severe allergy or contraindication to vascular interventional-related drugs or devices, such as aspirin, clopidogrel, general anesthesia agents, heparin, contrast agents, nitinol alloy, etc.\n17. Active bleeding diathesis or coagulopathy, active gastrointestinal ulcer, major systemic hemorrhage within 30 days, active bleeding diathesis, platelets count \\\u003C100,000, hematocrit \\\u003C30, INR \\>1.5, dysfunctions of the blood coagulation system.\n18. uncontrolled severe hypertension (systolic BP\\>180mm Hg or diastolic BP\\>110mm Hg)\n19. Severe comorbidities or unstable conditions, such as severe heart failure, respiratory failure, or renal failure (serum creatinine\\>264μmol\u002FL, unless on dialysis), severe liver dysfunction (ALT or ALT \\>3 times normal), malignant tumors.\n20. Major surgery performed within 30 days prior to enrollment or planned inpatient surgery within 90 days after enrollment.\n21. Pregnancy or intent to become pregnant during the trial period.\n22. Currently participating in another clinical trial.\n23. Life expectancy less than 3 years\n24. Patients unable to complete follow-up due to cognitive impairment, emotional disorders, or mental illness.",{"count":163,"type":21},536,[56],"A multicenter, open-label, blinded-endpoint, prospective, randomized controlled clinical trial with an \"all comers\" design.",[26],[62,168],"Cerebral Arteriosclerosis","2023-08-01",{"date":171,"type":35},"2023-08-03",{"date":173,"type":21},"2023-08",{"date":175,"type":21},"2027-12",{"name":73,"class":42}]